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Sepsis remains the leading cause of death in most intensive
care units. Advances in understanding the immune response
to sepsis provide the opportunity to develop more effective
therapies. The immune response in sepsis can be characterized
by a cytokine-mediated hyper-inflammatory phase, which
most patients survive, and a subsequent immune-suppressive
phase. Patients fail to eradicate invading pathogens and are
susceptible to opportunistic organisms in the hypo-inflammatory phase. Many mechanisms are responsible for sepsisinduced immuno-suppression, including apoptotic depletion
of immune cells, increased T regulatory and myeloid-derived
suppressor cells, and cellular exhaustion. Currently in clinical
trial for sepsis are granulocyte macrophage colony stimulating factor and interferon gamma, immune-therapeutic agents
that boost patient immunity. Immuno-adjuvants with promise
in clinically relevant animal models of sepsis include anti-programmed cell death-1 and interleukin-7. The future of immune
therapy in sepsis will necessitate identification of the immunologic phase using clinical and laboratory parameters as well as
biomarkers of innate and adaptive immunity.

Introduction
Sepsis is the major cause of death in most intensive care units
in the United States with approximately a quarter of a million
deaths annually. Although new treatment algorithms focusing on
rapid administration of broad spectrum antibiotics and aggressive restoration of tissue oxygen delivery have led to decreases
in mortality, the death rate is still 30%.1,2 Microbial virulence
factors, the extent of bacterial tissue invasion, and patient
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Submitted: 07/11/2013; Revised: 09/16/2013; Accepted: 09/17/2013
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co-morbidities interact to drive the host response that includes a
wide array of manifestations including septic shock, adult respiratory distress syndrome (ARDS), multiple organ dysfunction
syndrome (MODS), and systemic inflammatory response syndrome (SIRS).3,4 The heterogeneity of the disease encompasses a
diverse interplay between immunological stimulation, systemic
inflammation, and coagulopathy which vary in degree from
patient to patient.5 This heterogeneity in patient response to sepsis is in part responsible for the over 30 failed clinical drug trials;
beyond supportive care, there is presently no specific Food and
Drug Administration-approved drug for the treatment of sepsis
in humans.6 In this review we will focus on (1) the role of the
adaptive immune system and detail its contribution to the host
response in sepsis and (2) outline novel potential targets for individualized immune therapy in these patients.

Pro-Inflammatory Response: Cytokine Storm
Septic patients frequently present with fever, shock, and respiratory failure due to an uncontrolled pro-inflammatory response
that has been termed SIRS.7 This initial immune recognition
response is mediated by pathogen-associated molecular patterns
(PAMPs) and danger-associated molecular patterns (DAMPs)
originating from bacterial or fungal organisms and the host
upon injury, respectively, that bind pattern recognition receptors
expressed on innate immune cells.3,4,8 The activation of pattern
recognition receptors results in the production of numerous proinflammatory molecules including TNF-α, IL-1β, IL-2, IL-6,
IL-8, and IFN-γ and anti-inflammatory cytokines that induce
a panoply of cellular responses and counter-responses. These
responses include but are not limited to enhanced phagocytic
activity, vascular endothelial injury with capillary leak, synthesis
of acute phase proteins by the liver, chemotaxis of leukocytes to
sites of infection/inflammation, and activation of the coagulation system.3,4,8,9
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for therapeutic intervention.11 Clinical trials included, for
example, TNF and IL-1β antagonists, toll-like receptor (TLR)
blockers, platelet activating factor inhibitors (Xigris12-14), anticoagulants, endotoxin antagonists, hemofiltration to remove
soluble endotoxin and cytokines, and blocking super-antigens
which ultimately showed no benefit or, in some cases, worsened
outcome.11,15-17

Hypo-Inflammatory Response: Immuno-Paralysis

Figure 1. Immune response in sepsis. The immune response in sepsis
is determined by many factors including co-morbidities (i.e., diabetes,
heart disease, malignancy) as well as the pathogen virulence and size
of the microbial inoculums. Although both pro- and anti-inflammatory
processes are activated simultaneously during the onset of sepsis, during the first few days, a hyper-inflammatory response often dominates
the clinical picture. The hyper-inflammatory phase has been termed a
“cytokine storm” that is indicated by increased levels of TNF-α, IL-1β,
and IL-6. A robust depletion of both innate and adaptive immune cells
through apoptosis occurs to dampen the response. (A) At this stage,
patients may undergo a controlled anti-inflammatory response enabling
them to return to immune homeostasis. Alternatively, patients may
undergo an uncontrolled anti-inflammatory response and enter a hypoinflammatory phase yet survive (B) or succumb. Protracted time spent in
this hypo-inflammatory phase may lead to cellular exhaustion; a cellular
phenotype indicated by impaired function as well as increased PD-1 and
decreased IL-7R expression on T lymphocytes. In this phase, patients fail
to mount proper immune responses leading to viral re-activation and
secondary infections, frequently caused by avirulent and opportunistic
organisms and of ventilator-associated pneumonia.

The coagulation system is closely linked to inflammation
predominately through the innate immune response. In sepsis,
inflammation is accompanied by coagulation activation, thrombin generation, and disseminated intravascular coagulation
(DIC).10 The primary coagulation pathway activated in sepsis is
the tissue factor pathway which results in upregulation on monocyte/macrophage membranes and damage to the endothelium.10
The intrinsic or contact factor pathway amplifies clotting in an
autoactivation manner leading to widespread vasodilation and
generation of bradykinin.10 Ultimately, the rapid consumption
of coagulation factors leads to diffuse hemorrhaging in sepsis.10
Protease-activated receptors on activated endothelial cells, neutrophils, and monocytes bind to thrombin, factor Xa, and tissue
factor:VIIa which increases the synthesis of pro-inflammatory
mediators IL-6, IL-8, and adhesion molecules.10 This adhesion
molecule expression on the vasculature recruits activated leukocytes, in particular activated neutrophils which produce lytic
enzymes, reactive oxygen species, and nitrogen intermediates
that contribute to microcirculatory and organ failure.10
Initially the pro-inflammatory response was believed to be
the major cause of mortality in sepsis and was heavily targeted

As patients survived the initial hyper-inflammatory, cytokine storm phase of sepsis, it became apparent that many septic patients developed a delayed and potentially prolonged
counter-regulatory, anti-inflammatory state. This was initially
referred to as a compensatory anti-inflammatory response syndrome (CARS).18-21 After considerable debate, a consensus
developed that, sepsis can evolve into two phases: the first being
hyper-inflammation (cytokine storm) and the second being
hypo-inflammation (immune-paralysis)15,22 (Fig. 1). Although
inflammation in sepsis is presented as a biphasic view in this
review, genome-wide transcription profiling in human sepsis has
indicated that mechanisms of pro- as well as anti-inflammatory
mechanisms occur during variable times over the course of sepsis.23,24 However for the purpose of this review, the biphasic model
explains the net effect on the inflammatory response, including both innate and adaptive immune function, where patients
may cycle through each phase multiple times over the course of
sepsis.15 This biphasic view maybe a simplistic explanation of
a complex disease, yet provides a rational explanation for how
the function of the immune system becomes altered during the
course of sepsis. The intensity of the initial hyper-inflammatory
phase varies depending upon a multitude of factors including the
patient’s underlying physical state and co-morbidities, pathogen
virulence factors, pathogen load, and genetic factors. Following
this, perhaps in an effort to dampen systemic inflammation, subsequent immunosuppression may develop. As with the uncontrolled initial inflammation, this may overshoot and result in
immune dysfunction that leads to increased host susceptibility
to secondary bacterial infections (ventilator-associated pneumonia [VAP]),25 infections with typically avirulent or opportunistic
organisms,26,27 reactivation of latent herpes viruses (cytomegalovirus [CMV]),28-30 increased risk of MODS,31 and loss of delayed
type hypersensitivity response to common recall antigens.32
Research by many groups has shown that hypo-inflammation
is due to a variety of immune defects including a dysfunctional
adaptive immune response.15,33-40
The adaptive immune system consists of specialized cells
that are antigen specific and critical for generating memory and
recall responses to antigens. Antigen-specific T cells are necessary for driving specific responses against intracellular (T-helper
1 [Th1]) or extracellular pathogens (T-helper 2 [Th2]) by cellto-cell contact mechanisms or through soluble mediators (cytokines). CD4 T cells are typically classified as helper T cells
and control cells of the adaptive system. CD8 T cells are classified as cytotoxic (CTL) and kill targeted cells such as virally
infected or tumor cells. Antibody production, termed humoral
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immunity, by B cells requires T-cell help. Antigen-specific antibody can neutralize toxins, fix complement, and coat the surface
for phagocytic uptake of pathogens by monocytes/macrophages.
Antigen-presenting cells, including monocyte/macrophages and
dendritic cells, sample the environment and present antigens to
T cells for initiation of immune responses or induction of tolerance of the adaptive immune response. The effects of sepsis
on the adaptive immune response and the potential therapeutic
advantage of targeting these components during the pathogenesis
of sepsis will be the focus of the following sections.

Adaptive Immunity: Apoptosis
of Immune Effector Cells
Programmed cell death, also called apoptosis, is one way in
which the immune system maintains homeostasis by eliminating activated cells. Central to apoptosis are caspases which are
cysteine proteases that degrade cellular proteins and NFκB, a
transcription factor which will activate transcription of both proapoptotic and pro-survival genes. While the hyper-inflammatory
response of sepsis requires NFκB for production of pro-inflammatory cytokines and IL-1β activation by caspase cleavage, both
NFκB and caspases concurrently induce apoptosis of adaptive
immune cells.8,41,42 Consistent with this, a concurrent apoptotic
response has been shown to be present in sepsis in association
with the pro-inflammatory response. Our group has shown both
in mouse models of sepsis43,44 as well as most recently in patients
with severe sepsis that there is a profound depletion of T, B, and
dendritic cells.45-48 Within the first 24 h of sepsis diagnosis in
humans, marked lymphopenia occurs which is due to recruitment of lymphocytes from the circulation to sites of inflammation/infection and to apoptotic depletion of CD4 and CD8
T cells in the blood.45 Postmortem analysis of spleens and lymph
nodes from individuals who succumbed to sepsis confirmed the
highly significant loss of CD4 and CD8 T cells.46 Memory CD8
T cells are highly susceptible to apoptosis in systemic inflammatory states such as septic shock and are depleted in sepsis.49 These
results indicate that depletion of adaptive immune cells is a major
pathologic component of sepsis with potential debilitating effects
on host immunity.
Although the depletion of adaptive immune cells is recognized as an important part of the pathology of sepsis, the mechanisms responsible for this are not totally understood.50,51 In
general apoptosis is divided into two mechanistic pathways, i.e.,
an extrinsic pathway that conveys a signal through a death receptor such as the tumor-necrosis family of receptors (i.e., CD95/
CD95L, TNF/TNFR) or an intrinsic pathway that disrupts
mitochondrial integrity resulting in release of cytochrome C.52,53
The activation of caspase 8, through death domains, and/or the
activation of caspase 9, by the release of cytochrome C, results
in the cleavage and activation of caspase 3 an effector caspase
that induces extensive substrate cleavage of many critical proteins
ultimately leading to cell death.52,53 These pathways of apoptosis
have multiple points of crosstalk.54 Bid, a member of the Bcl-2
family of proteins, is cleaved by activated caspase-8, an effector
of the extrinsic pathway, to form truncated Bid.54 This truncated

Bid translocates to the mitochondrion where it binds Bax/Bak,
members of the Bcl-2 family associated with the intrinsic pathway, to further induce apoptosis.54 Heat-shock proteins can either
be constitutively expressed or rapidly induced in response to
stress, like inflammation, yet modulate both the mitorchondrial
and receptor mediated apoptotic pathways.54 Adaptor molecules
like receptor interacting protein (RIP) or members of the TNF
receptor-associated factor family (TRAF) activate transcription factor families associated with both survival and apoptosis
including NFκB and mitogen-activated protein kinase (MAPK)
pathways.54 To add to this complexity, a wide range of protein
modifications and interactions form diverse yet interconnected
signaling cascades that regulate signaling pathways such as PI3KAkt/PKB, Ras-Raf-Mek-Erk MAPK, NFκB, and protein kinase
C that are pro-survival while JNK/p38 stress MAPK or ROS/
ceramide-mediate signaling which are pro-apoptotic.54
As noted earlier, CD4 and CD8 T cells are highly susceptible
to sepsis-induced apoptosis. To test the premise that soluble factors induce lymphocyte apoptosis in sepsis, serum from patients
with SIRS was added to cultures of lymphocytes from healthy
volunteers. Apoptosis of CD4 T cells was observed when plasma
from SIRS patients was added but apoptosis was not present
when serum from healthy donors was used.55 Although this soluble factor has yet to be identified, it is likely that a multitude of
soluble factors are involved in modulating lymphocyte apoptosis.
Some gram-positive bacteria have a unique property, an exotoxin
termed a superantigen that activates CD4 T cells through a tetrad signaling complex consisting of a correctly folded superantigen, the CD28 dimer interface, Vβ loop of the TCR, and a
binding site outside the epitope presenting groove on MHC class
II molecules.56 This interaction occurs independent of MHCClass II molecules and results in rapid activation, secretion of
pro-inflammatory cytokines and ultimately cell death.8 In polymicrobial sepsis the activation of the peroxisome proliferator activated receptor (PPARγ) leads to decreased IL-2 gene expression, a
T-cell survival factor that induces expression of the potently antiapoptotic protein Bcl-2.57 The massive release of TNF-α early in
sepsis results in activation of additional pro-inflammatory cytokines and chemokines which act in conjunction with TNF-α to
induce T-cell apoptosis.58 In mouse models of sepsis, the complement factor C5a binds to the receptor C5aR on thymocytes and
induces apoptosis.59 Therefore, in sepsis a diversity of soluble factors are present that potentially regulate apoptosis and add to the
heterogeneity of sepsis pathology.
Lymphocyte fate is determined by the balance of pro- vs antiapoptotic mechanisms. In our postmortem study of sepsis, we
documented decreased expression of CD28 on T lymphocytes
on septic patients when compared with control patients.46 The
co-stimulatory molecule CD28, when engaged by B7 molecules
on antigen presenting cells, is an essential requirement for IL-2
production and Bcl-X L expression, both pro-survival factors of
T cells.60 Antigen-presenting cells, including dendritic cells and
monocytes/marcrophages, isolated from either the spleen or the
lung of septic patients also had decreased expression of B7 molecules (B7-1/CD80 and B7-2/CD86) potentially limiting the ability of T cells to receive co-stimulation.46 Without the necessary
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co-stimulation through CD28/B7 when the T-cell receptor
engages antigen, T cells will undergo a process termed death by
neglect or become functionally unresponsive (anergic).
Our recent studies have also indicated that T cells upregulate surface receptors that inhibit T-cell functions. We identified increased expression of programmed death receptor-1
(PD-1), CTLA-4, and B and T lymphocyte attenuator (BTLA)
on T cells when isolated from postmortem spleen and lung as
well as from blood 7 days after initial diagnosis with sepsis.45,46
Furthermore, we detected increased expression of the ligands for
PD-1, programmed death ligand-1 and -2 (PD-L1 and PD-L2),
on antigen-presenting cells isolated from the blood after 7 days
of initial septic diagnosis and from lymphocytes isolated from
post-mortem spleen and lung.45,46 The expression of PD-L and
herpesvirus entry mediator (HVEM), the ligand for BTLA, was
observed on the epithelium and on macrophages of the lung in
septic patients.45,46 The expression of PD-L on antigen presenting
cells and endothelial cells has been associated with the induction of tolerance,61,62 providing a mechanism where the tissue
regulates lymphocyte homeostasis. The engagement of PD-1,
CTLA-4, or BTLA, all members of the CD28-superfamily of
receptors, results in T-cell apoptosis or cellular unresponsiveness
that aid in returning the host to immune homeostasis.63 PD-L
and CTLA-4 as well as TNFR ligand family members such as
Fas-Ligand (CD95L) are expressed on a specialized type of CD4
T cell that expresses the transcription factor FoxP3 and high surface levels of CD25 (IL-2Rα) termed regulatory T cells (Tregs).64
Regulatory T cells are capable of suppressing T-cell proliferation,
cytokine secretion and induce T-cell apoptosis.65 These cells are
increased in percentage in septic patients due to their resistance
to apoptosis and a decrease in CD4 + CD25− T cells35,36,45,66,67 provides yet another potential mechanism of immune dysfunction.
The expression of these inhibitory receptors/ligands on T cells,
antigen presenting cells and tissue presents an environment that
is conducive to T-cell depletion and unresponsiveness in septic
patients.

Adaptive Immunity: Cellular Hypo-Responsiveness
The anti-inflammatory cytokine IL-10 has been detected in
serum of septic patients very early during their illness.68 A high
ratio of IL-10 to TNF-α in septic patients correlated with mortality in patients with community acquired infection.68,69 The
anti-inflammatory cytokine IL-10 is produced by Tregs and Th2
type cells and suppresses the Th1 (CD8 T cell) response further
potentiating an anti-inflammatory environment.70,71 This suppressive environment results in a marked decrease in stimulated
monocyte production of pro-inflammatory cytokines TNF-α,
IL-1β, and IL-6 (typically less than 10–20% that of healthy
controls).72-76 This compensatory anti-inflammatory response
syndrome, or immune-paralysis as it was originally referred to,
is mediated by a predominance of a Th2 response, increased
Tregs, apoptosis of lymphocytes and decreased MHC class II
(HLA-DR) molecules on monocytes/macrophages.10,18 Our
group reported that immune effector cells isolated from postmortem spleens with patients dying of sepsis and peripheral blood

mononuclear cells isolated from blood of septic individuals 7 days
after onset of sepsis have impaired secretion of both pro- and
anti-inflammatory cytokines (TNF-α, IFN-γ, IL-6, IL-10).45,46
Furthermore, this cytokine secretion defect in septic patients was
present after stimulation with lipopolysaccharide (a monocyte/
macrophage activator) and after stimulation with anti-CD3/antiCD28 (a T-cell activator) indicating that both the innate and
adaptive immune systems are suppressed.45,46

Adaptive Immunity: Cellular Exhaustion
Both the postmortem and prospective blood study, previously
discussed, demonstrated that T lymphocytes from septic patients
expressed inhibitory receptors and that these T cells were unable
to produce cytokines after ex vivo stimulation.45,46,77 In the postmortem study, T cells isolated from the spleen had increased
expression of CD69, PD-1, and CD25 and decreased expression
of the IL-7 receptor (IL-7R, CD127) and CD28 when compared
with age-matched controls.46 T cells isolated from the lung had
increased expression of PD-1 and BTLA indicating a degree of
tissue specificity in sepsis.46 Furthermore, increased expression of
inhibitory receptors, PD-1, BTLA, CTLA-4, T cell membrane
protein-3 (TIM-3), lymphocyte-activation gene-3 (LAG-3), and
decreased expression of the IL-7R on T cells isolated from the
blood of septic patients occurs over the course of sepsis.45 This
expression of inhibitory receptors and decreased cytokine secretion resemble a recently described phenotype observed in chronic
viral infections like HIV and hepatitis C that is termed cellular
exhaustion.
T-cell exhaustion is a step-wise progressive loss of T-cell functions in the presence of high antigen load that can result in T-cell
deletion.78 Originally described in the lymphocytic choriomeningitis virus (LCMV) mouse model, T-cell exhaustion has also
been documented in HIV, hepatitis C, hepatitis B, polyoma
virus, adenovirus, Friend leukemia virus, and in malignancies.78
Exhausted T cells have high expression of CD69, CD43 (1B11),
PD-1, TIM-3, and LAG-3, low expression levels of CD62L and
CD127 (IL-7R), increased expression of the transcription factor BLIMP-1 (CD8 T cells) and decreased secretion of TNFα, IL-2, IFN-γ, and Granzyme B.78 The engagement of PD-1
by its ligands on exhausted T cells results in IL-10 production,
functional unresponsiveness and/or apoptosis.78 In sepsis, there
is high antigen load due to chronic infection, T cells acquire
expression of inhibitory receptors over time, as well as the expression of inhibitory ligands on antigen presenting cells and in a
tissue-specific manner, provide a unique environment for T-cell
exhaustion as an additional mechanism of immune suppression in sepsis.45,46 In support of this concept of sepsis-induced
T-cell exhaustion, tissue expression of PD-L and HVEM the
ligands for PD-1 and BTLA on T cells was present in the lungs
of septic individuals but not in lungs of transplant recipients or
age-matched non-septic control patients.46 These findings are
particularly relevant given the high incidence of ventilator associated pneumonia which is the most common nosocomial infection in the intensive-care unit.79-81 The increased susceptibility
of the lung to secondary infection in septic patients may be due
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Table 1. Immune enhancing therapy: clinical trials in sepsis
Agent

Study

Outcomes

References

G-CSF

RCT in patients with pneumonia and severe
sepsis

Increased WBC counts
No reduction in mortality
Well tolerated

Root et al.103

G-CSF

RCT in patients with multilobar pneumonia

Increased WBC counts
Reduction in mortality (trend)
Well tolerated

Nelson et al.101

GM-CSF

RCT in patients with sepsis or septic shock and
sepsis induced immunesuppression

Increased HLA-DR expression
Restored cytokine secretion in monocytes
Improved patient outcomes

Meisel et al.105

GM-CSF, rIFN-γ
(ongoing)

Effects of immunostimulation with GM-CSF or
IFN-γ on immunoparalysis following human
endotoxemia

Cytokine secretion by lymphocytes
HLA-DR expression
Monocyte/neutrophil function
Lymphocyte gene expression
Volunteer responses

NCT01374711

rIFN-γ

RCT in trauma patients

Increased HLA-DR expression
Decreased severe infections (trend)

Polk et al.106

rIFN-γ

RCT in patients with burns

No improved patient outcomes

Wasserman et al.107

rIFN-γ

RCT in trauma patients

Reduced infection related deaths

Dries et al.108

Effects of interferon-gamma on sepsis-induced
immunoparalysis

Cytokine secretion by lymphocytes
HLA-DR and receptor expression (PD-1)
Lymphocyte gene expression
Reversibility of monocyte dysfunction
Patient outcomes

NCT01649921

rIFN-γ (ongoing)

Thus far, the focus of enhancing immune function in sepsis has been limited to trials for GM-CSF or G-CSF, a stimulator of the innate immune system, and
IFN-γ, a stimulator of the adaptive immune system. Abbreviations: RCT, randomized controlled trial; GM-CSF, granulocyte-macrophage colony-stimulating factor; G-CSF, granulocyte colony-stimulating factor; rIFN-γ, recombinant interferon gamma; PD-1, programmed death receptor-1; WBC, white blood
cell count; NCT, ClinicalTrials.gov identifier.

in part to expression of inhibitory ligands on lung parenchyma
resulting in local T-cell exhaustion.

Immuno-Therapy: Targeting the
Adaptive Immune System
Despite active research in understanding human sepsis, the
number of registered human clinical trials is disappointing,
with most observational in nature and few being interventional
(Table 1). Many septic patients have a relatively short-lived
hyper-inflammatory phase; therefore, the success of drugs targeting inflammation has only a narrow time frame to be effective.
The keys to drugs targeting this hyper-inflammation are: drugs
should be short lived, applied early and used only in patients
with elevated levels of pro-inflammatory cytokines (i.e., TNFα, IL-1β, or IL-6).3,4 Phase I–III clinical trials using drugs to
reduce this pro-inflammatory cascade have had disappointing
results in 28-day mortality rates in septic patients when compared with placebo-treated controls.14,17,82-90 Most septic patients
residing in ICUs have survived the hyper-inflammatory stage
of the disease yet have prolonged periods of hospitalization and
recovery with the potential to become immune compromised
and develop nosocomial infections and/or multiorgan dysfunction.34,91,92 Therefore, one of the keys to decreasing mortality
in sepsis may be the development of therapies to augment host
immune responses. Collectively, results of studies designed to
block this hyper-inflammatory phase suggest partial benefit in

early onset sepsis in highly-defined populations of septic patients
yet are potentially detrimental to septic patients who have progressed into immune-paralysis.15,33
Even before the molecular pathophysiology of sepsis was
thoroughly understood, investigators attempted to stimulate the
innate and adaptive immune systems with IFN-γ, granulocyte
macrophage colony stimulating factor (GM-CSF) or granulocyte
colony stimulating factor G-CSF. In an attempt to reverse monocyte/macrophage dysfunction and increase IL-17, a cytokine necessary for the recruitment of neutrophils to the infected site, septic
patients were treated with IFN-γ.93 Treatment with GM-CSF was
also predicted to reverse the dysfunction of dendritic cells and
macrophages/monocytes.94 G-CSF was utilized to increase numbers of polymorphonuclear leukocytes, in an effort to enhance
pathogen clearance. Although a recent meta-analysis performed
on GM-CSF and G-CSF studies conducted from 1998 to 2011
failed to show survival benefit,95 some studies did show limited
efficacy on research endpoints.96-105 In summary, GM-CSF or
G-CSF treatment increased neutrophil phagocytosis, resolved
infections earlier, decreased secretion of toxic metabolites,
increased expression of CD11b and HLA-DR on neutrophils/
monocytes, and reversed immune-paralysis in selected septic
patients.3,4 Two recent small phase 2 trials of GM-CSF that have
targeted its use to septic patients with low monocyte HLA-DR
expression have shown benefit. Mechanically-ventilated patients
with sepsis that received GM-CSF had improved health evaluation scores, shortened time of mechanical ventilation, and an
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Table 2. Clinical trials for the immune system in sepsis
Identifier

Title

Study type

Sponsor

NCT01600989

Mitochondrial Function of Immune Cells in Sepsis (MitoSepsis)
(2012)

Observational

University Hospital Inselspital

NCT01530932

Immune Activation, Hypoxia and Vasoreaction in Sepsis of
Pulmonary Vs. Abdominal Origin (2011)

Observational

University Hospital Mannheim

NCT00187824

Regulation of Endocrine, Metabolic, Immune and Bioenergetic
Responses in Sepsis (2005)

Observational

University College London Hospital

NCT01410526

Assessment of Peritoneal Immune Response in Patients with
Severe Intra-abdominal Sepsis Managed with Laparostomy
and Vacuum Assisted Closure (VAC) (2011)

Observational

Aristotle University of Thessaloniki

NCT01472952

System-level Monitoring of Immune Activation Concerning
Susceptibility to Sepsis in Trauma Patients (2011)

Observational

University Hospital Mannheim

NCT01155674

Innate Immune Functions of Immature Neutrophils (2010)

Observational

University Hospital Geneva

NCT01766414

In Vivo Effects of C1-esteraase Inhibitor on the Innate Immune
Response During Human Endotoxemia – VECTOR II (2013)

Interventional

Radboud University

NCT01649921

The Effects of Interferon-gamma on Sepsis-induced
Immunoparalysis (2012)

Interventional

Radboud University

NCT00294697

Genetic Variation and Immune Response After Injury (2006)

Observational

National Institute of General Medical
Sciences

NCT00638521

Immune-cell Membrane Trafficking (2008)

Observational

University of Washington

NCT01099813

Sepsis Pathophysiological and Organisational Timing
(SPOT[Light]) (2010)

Observational

Intensive Care National Audit and
Research Centre

NCT01756755

Endotoxin Adsorber Hemoperfusion and Microcirculation
(2012)

Interventional

National Taiwan University Hospital

NCT01275976

Effect of C1-esterase Inhibitor on Systemic Inflammation in
Trauma Patients with a Femur Fracture (CAESAR) (2011)

Interventional

UMC Utrecht

NCT01005589

CD64 Meaurement in Neonatal Infection and Necrotising
Enterocolitis (2009)

Observational

Newcastle-upon-Tyne Hospitals NHS
Trust

NCT00527384

Biomarker Analysis of Stress (2007)

Observational

National Institute of Environmental
Health Sciences

NCT01397058

Reactivation of CMV Infection in Immunocompetent Patients
Under Severe Stress (RECYSTRESS) (2011)

Observational

University of Athens

NCT01374711

Effects of Immunostimulation with GM-CSF or IFN-γ on
Immunoparalysis Following Human Endotoxemia (2011)

Interventional

Radboud University

NCT01653665

Does GM-CSF Restore Neutrophil Phagocytosis in Critical
Illness? (2012)

Interventional

Newcastle-upon-Tyne Hospitals NHS
Trust

A search on ClinicalTrials.gov was performed using the search terms “Sepsis and Immune” (48 studies) or “Sepsis and Biomarkers” (74 studies) filtered by
“open studies”. This represents a list of the current open and enrolling clinical trials for sepsis in regards to the immune system. Interestingly, most clinical
trials in sepsis have been initiated within the past 10 years as indicated by the start date of the clinical trial in parenthesis following the trial title.

accompanied increased HLA-DR expression and in secretion
of pro-inflammatory cytokines (IL-6 and TNF-α) ex vivo as
compared with controls.105 At least 2 clinical trials of GM-CSF
are currently enrolling patients in sepsis (NCT01374711 and
NCT01653665, Table 2), so it will be highly interesting to
observe these results when they become available.
Thus far, the only attempt to modulate the adaptive immune
response in a sepsis clinical trial was the administration of IFN-γ
(Table 2). Treatment with IFN-γ in critical illness has yielded
conflicting results. In two multi-center trials with patients of
trauma and burns, treatment with IFN-γ had no effect when
compared with placebo.106,107 However, in an additional trial in
burn patients, IFN-γ treatment reduced infection-related deaths

when compared with placebo.108 Interestingly, when IFN-γ was
co-administered with GM-CSF to those septic patients whose
mononcytes had decreased HLA-DR expression of less than 35%
of normal, therapy raised HLA-DR co-expression up to ~50%
and restored TNF-α secretion from ex vivo stimulated peripheral blood mononuclear cells.109 These results further confirm
the importance of knowing the relative pro- and anti-inflammatory balance of the septic patients before administering immune
therapies in sepsis. In our prospective study of septic patients,
IFN-γ was determined to be the cytokine that was significantly
decreased at the earliest time point following sepsis onset.45
Furthermore, peripheral blood mononuclear cells isolated from
septic individuals that were rested overnight in fresh media
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recovered their ability to secrete IFN-γ in response to ex vivo
stimulation.45 These data suggest depressed secretion of IFN-γ is
an early indicator of hypo-inflammation and may be a reversible
defect in lymphocytes; therefore, pathways that augment IFN-γ
may be good potential therapeutic targets. Currently Radboud
University in the Netherlands is conducting an IFN-γ trial in
sepsis to study the effects on “sepsis-induced immunoparalysis”,
which will be completed in December 2013 (ClinicalTrials.gov;
NCT01649921).
In addition to GM-CSF, G-CSF, and IFN-γ, other novel
immune-adjuvant therapies may be effective in augmenting the
adaptive immune system and restoring immunity. The profound
apoptosis-induced depletion of lymphocytes in sepsis is one such
attractive therapeutic target. The pro-survival cytokines IL-7
and IL-15 have had promising results in sepsis models in preventing lymphocyte apoptosis and restoring adaptive immunity.
In a mouse model of sepsis, IL-15 treatment increased lymphocyte survival, decreased apoptosis of natural killer cells, dendritic
cells, and T cells, and increased IFN-γ secretion.110 The administration of IL-15 may have additional benefits of increasing natural killer and dendritic cell survival111,112 whereas IL-7 is thought
to be a more T cell targeted cytokine.113
Currently, the most promising cytokine in restoring T-cell
function in a variety of disease states is IL-7. IL-7 is a pluripotent cytokine of the immune system that affects both T
and B cells and induces proliferation of naïve and memory T
cells.113,114 Administration of IL-7 by investigators at the National
Cancer Institute to cancer patients led to a doubling of CD4
and CD8 T cells, did not expand regulatory T cells, and led to
a corresponding increase in spleen and lymphnodes by roughly
50%.115-117 Recombinant IL-7 was also effective in inducing a
doubling of circulatory CD4 and CD8 T cells in patients with
lymphopenia due to HIV.118 Several groups including ours have
shown that IL-7 treatment of mouse models of sepsis results in
increased lymphocyte numbers, restored delayed type hypersensitivity responses, decreased lymphocyte apoptosis, reversed the
impaired IFN-γ secretion of lymphocytes and improved survival.93,119,120 Furthermore, work by Venet et al. showed that IL-7
treatment of isolated lymphocytes from septic patients restored
T-cell proliferation, IFN-γ secretion, STAT5 phosphorylation
(an important downstream signaling molecule of the IL-7R), and
Bcl-2 expression close to that of healthy controls.121 Treatment of
HIV and cancer patients with hIL-7 has indicated IL-7 is well
tolerated with less side effects then IL-2, another pro-survival
cytokine for T cells, and has diverse effects including: increases
in T-cell survival, restores function in exhausted T cells a phenotype identified in sepsis,77 increases expression of adhesion molecules and therefore trafficking to sites of infection, and increases
T cell receptor diversity thereby increasing pathogen recognition.118,122-124 Due to the diverse effects of IL-7 on the adaptive
immune system and its good safety clinical profile, IL-7 has been
consistently ranked as one of the top therapeutic molecules by
the NCI.125 Therefore, we believe clinical trials of IL-7 in sepsis
should be initiated.
Common to most septic patients is increased expression of
PD-1 on T cells over the progression from hyper-inflammation

to hypo-inflammation. As noted earlier, signaling through
PD-1 inhibits T-cell proliferation, induces IL-10 secretion,
induces apoptosis and anergy, and inhibits cytotoxicity of CD8
T cells.126,127 Four independent groups have shown that disruption of the PD-1/PD-L axis either by genetic deletion or by
pharmacologic manipulation improved survival in bacterial and
fungal murine sepsis.128-131 In both our prospective and postmortem studies of septic patients, PD-1 expression was increased
on CD4 and CD8 T cells while PD-L expression was increased
on antigen presenting cells as well as on the tissue of the spleen
and lung45,46 indicating this PD-1/PD-L axis is present and may
be dysregulated in human sepsis. Furthermore, PD-1 overexpression on T cells from septic patients correlated with decreased
T-cell proliferation, increased secondary infections and mortality.132 In oncology, anti-PD-1 and anti-PD-L antibody therapy
has been used successfully to treat various tumors in 20–25% of
treated patients.133,134 These data indicate that blocking the PD-1/
PD-L axis is a promising target for restoring immune function in
human sepsis.
As T-cell exhaustion is defined by the expression of multiple
inhibitory receptors, not just PD-1 expression, the development
of blocking antibodies to these additional receptors may also be
promising in sepsis.77 For example the BTLA/HVEM axis also
a negative regulator of T-cell responses135,136 is also present in
human sepsis. Interestingly, T cells express BTLA while tissue
of the lung, a common site of secondary nosocomial infections
including ventilator-associated pneumonia, expresses HVEM.45,46
BTLA deficient mice have increased survival in a mouse model
of sepsis,137 providing another immunologic target for ventilator
associated pneumonia and sepsis. Additional receptors associated
with T-cell exhaustion such as TIM-3, LAG-3, and CTLA-4
may also provide therapeutic targets in restoring T-cell functions.
Cellular exhaustion is a characteristic not only of chronic viral
infections but of cancer biology due to the presence of high antigen load.138 In mouse models of tumor formation, anti-TIM-3
therapy reduced tumor burden and increased IFN-γ secretion
and cytotoxic ability of tumor-specific CD8 T cells.139,140 In
addition to TIM-3, LAG-3 therapy has shown promising results
in treating human cancers by restoring anti-tumor responses
of T cells.141 With our rapidly expanding knowledge of T-cell
exhaustion and the role of these inhibitory receptors in lymphocyte function, the potential for biologics that modulate the adaptive immune system and restore lymphocyte function in sepsis
offers great promise (Fig. 2).
In the not too distant future, one can imagine a way to genetically manipulate T cells for the treatment of sepsis. Genetically
modified T cells are currently in trial for the treatment of herpes viral infections in transplant patients (ClinicalTrials.gov;
NCT01646645 and NCT01535885). These T cells have been
manipulated to be specific against viral specific antigens.142 In
sepsis, a modified T cell resistant to apoptosis and polyclonal
for a variety of pathogens, including bacterial, fungal and viral,
could be transfused during immune dysfunction to restore
patient immunity. Preliminary evidence in mouse models of sepsis using genetically modified T cells that overexpress Bcl-2143-145
or Akt146 have resulted in increased T cell and mouse survival.
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Figure 2. Pathways of immune dysfunction and targets for immune enhancing therapy in sepsis. In the initial pro-inflammatory response of sepsis,
both the adaptive and innate immune systems are rapidly activated. This activation of monocytes, dendritic cells (DC), and macrophages (MAC), as well
as CD4 helper and CD8 cytotoxic T cells results in the release of pro-inflammatory cytokines (TNF, IL-6, IL-1β) and chemokines. This pro-inflammatory
response normally results in cellular activation and clearance of the primary pathogen (~~, pathogen). In the instance of a healthy individual, the immune
system maintains homeostasis by employing counter inflammatory mechanisms such as regulatory T cells (Tregs), apoptosis, production of cytokines,
expression of inhibitory receptors and myeloid-derived suppressor cells (MDSC) concurrently during inflammation. However, in some septic patients
these normal homeostatic counter inflammatory mechanisms remain elevated such as expression of inhibitory receptors including: programmed death
receptor -1 (PD-1), programmed death ligand (PD-L), B and T lymphocyte attenuator (BTLA), and herpesvirus entry mediator (HVEM) as well as the
production of the immune modulating cytokine IL-10. Immune dysfunction occurs as activated innate and adaptive immune cells undergo rapid apoptosis while in the presence of increased suppressor cell populations like Tregs or MDSC. The primary infection fails to be cleared and may progress into
immune suppression. Prolonged immune suppression and persistent antigen may result in T-cell exhaustion indicated by a T cell’s increased expression
of PD-1 and decreased expression of the IL-7R as well as a functional impairment that includes failure to proliferate, secrete cytokines, and kill target
cells. Potential targets for immune-therapy are indicted in the dotted GREEN line. Potential therapeutic targets include using blocking antibodies such
as anti-IL-10 to decrease Treg function; anti-PD-1 and anti-PD-L to reverse the induction of T-cell exhaustion; and anti-HVEM or anti-BTLA to block tissue
suppression of immune cells. IL-7 or IL-15 may be effective in blocking apoptosis and reversing cell exhaustion; GM-CSF to stimulate APC function by
increasing recruitment and HLA-DR expression; and IFN-γ to increase PMN recruitment and function.

Modified T cells incorporating a suicide gene would enable only
the modified T cells to be destroyed once the infection is cleared
leaving the patient’s own immune system intact.147,148 This would
eliminate a potential concern of autoimmunity from long-term
antibody therapy.

Final Thoughts: Immune-Enhancing Therapy
Many trials using immune-modulatory agents have yielded
discouraging results in human clinical trials for sepsis.3,4 One
reason for this failure is that animal studies may not always correlate with the human condition. As the majority of sepsis models use genetically similar young mice, confounding problems
that are often present in clinical sepsis like age, genetic diversity,
underlying co-morbidities, various sites of infections, susceptibility to virulence factors, and management protocols including
nutrition and antibiotic usage are not accounted for.3,4,149,150 This
heterogeneity of human sepsis is in part what makes performing
clinical trials and their success very difficult to achieve. Recently,
genetic profiling of inflammatory diseases in humans and mice

have indicated that mouse gene transcriptional changes occurring in sepsis do not correlate with the human condition.151 These
data indicate the need to undertake more human translational
approaches to better our understanding of the underlying molecular pathophysiology of sepsis (Table 1).
To monitor sepsis in humans, clinical trials are currently
underway to elucidate biomarkers that can identify patients who
have increased or decreased inflammation (ClinicalTrials.gov,
Table 1). Importantly, the kinetics of expression of the targeted
receptors (i.e., PD-1/PD-L, HVEM/BTLA) as well as patient’s
immune status needs to be fully understood so that therapy
can be employed effectively. For example, inhibition of IL-10
in patients with increased inflammation dramatically increased
pro-inflammatory cytokines with detrimental effects.152 Clinical
trials that monitored HLA-DR expression as an indicator of
immune function had moderate success in improving outcomes
in sepsis.105,109 Therefore, a combination of flow cytometry for
lymphocyte expression of surface receptors (i.e., HLA-DR,
PD-1), functional assays for cytokine secretion (IFN-γ) as
well as presence or absence of nosocomial infections (ventilator
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pneumonia, Candida spp.) and reactivation of latent viruses (i.e.,
herpes viruses) may help to guide patient immune-therapy.
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